Please login to the form below

Not currently logged in
Email:
Password:

antibody-drug conjugates

This page shows the latest antibody-drug conjugates news and features for those working in and with pharma, biotech and healthcare.

Regeneron’s early stage bispecific shows promise

Regeneron’s early stage bispecific shows promise

Bispecifics and antibody drug conjugates will challenge CAR-Ts. The potentially revolutionary nature of CAR-Ts has made them the hottest properties in haemato-oncology in recent years, but a wave ... Another alternative platform is antibody-drug

Latest news

More from news
Approximately 5 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare 30 Women Leaders in UK Healthcare

    Current projects include developing antibodies for use as cancer imaging agents, antibody drug conjugates, chimeric antigen receptor therapies (CAR-Ts) and nano-medicines. ... and using efficient AI to generate a set of high-quality drug candidates.

  • Deal Watch February 2016 Deal Watch February 2016

    $26m Series A financing. The antibody, to be known as COR-001, will be progressed for cardiovascular applications. ... This month saw two existing partnerships that have been extended. Takeda has been working with Mersana Therapeutics since 2014 to

  • Pharma deals in April 2015 Pharma deals in April 2015

    The agreement also includes payment of double digit royalties.  . Innate also put in place a collaboration with Sanofi for next generation antibody-drug conjugates (ADCs) using Innate's site specific conjugation ... its SAR3419, an antibody-drug

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    1, 150. Sutro Biopharma/Celgene. Licence plus option to acquire Sutro. For development of multispecific antibodies and antibody drug conjugates (ADCs). ... 475. CureTech/Medivation. Exclusive global licence. For pidilizumab (CT-011), an immune modulatory

  • Pharma deals during October 2014 Pharma deals during October 2014

    An oncology deal for multispecific antibodies and antibody drug conjugates [ADCs], this transaction builds on the original deal signed in December 2012 with a headline of $500m. ... Keeping it flexible, Roche extended its 2013 licence agreement with

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

  • Crescendo Biologics appoints Peter Pack as CEO Crescendo Biologics appoints Peter Pack as CEO

    Crescendo is now shifting its focus to oncology with novel VH-based checkpoint modulators and humabody drug conjugate (HDC) therapeutics. ... We intend to expand rapidly our internal oncology programmes on checkpoint modulators and HDCs, which are a

  • ADC Therapeutics expands team ADC Therapeutics expands team

    Appointments preceed its first antibody drug conjugate trials. ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development. ... Oncology drug development company's new team

  • ImmunoGen hires VP product strategy ImmunoGen hires VP product strategy

    These programmes focus on antibody-drug conjugates (ADCs) to target cancers. The most successful of these ADCs so far is Kadcyla, which ImmunoGen developed with Genentech, now a part of Roche.

  • AVEO's financial head joins ImmunoGen AVEO's financial head joins ImmunoGen

    In his new role, Johnston will head the financial operations of one of the leading biotechs working to develop antibody-drug conjugates in cancer, with ImmunoGen's successes including the breast

  • CytomX makes senior changes following Pfizer deal CytomX makes senior changes following Pfizer deal

    CytomX Therapeutics has boosted both its senior science and business teams following a major antibody deal with Pfizer. ... Both positions will be crucial to supporting the San Francisco-based biotech's  growth following CytomX's  $635m deal agreed

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...
Investing in our People
As a small, boutique agency we can and do invest heavily in our team, who produce amazing results for our clients....

Infographics